Spermosens

Spermosens is a pioneering company in the field of reproductive health, specializing in the development of advanced medical devices aimed at diagnosing male factor infertility. Operating within the assisted reproductive technology (ART) market, Spermosens addresses a significant gap in infertility diagnostics, where 40% of male infertility cases remain unexplained. The company's core product, the JUNO Checked Instrument, individualizes In Vitro Fertilization (IVF) diagnostics and treatment, setting a new standard for faster and safer IVF procedures. Spermosens serves clinicians and fertility centers, providing them with tools to better understand and treat male infertility, thereby improving patient outcomes. The business model revolves around the sale and distribution of its diagnostic devices, supported by ongoing research and development to enhance product offerings. Revenue is generated through direct sales, partnerships, and licensing agreements. Listed on the Spotlight Stock Market since May 5, 2021, Spermosens continues to expand its market presence and technological capabilities.

Keywords: male infertility, IVF diagnostics, medical devices, reproductive health, fertility treatment, ART market, JUNO Checked, Spotlight Stock Market, biosensor technology, clinical tools.